Results 101 to 110 of about 4,025 (198)

Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.

, 2012
Fidaxomicin has recently been approved for the treatment of Clostridium difficile infection (CDI). As part of phase III studies, plasma and fecal samples were analyzed for concentrations of fidaxomicin and its metabolite, OP-1118.
Sears, P, Louie, TJ, Crook, DW, Miller, MA, Weiss, K   +4 more
core   +1 more source

Clostridioides difficile infection in hospital and community settings: summary document of a multidisciplinary group

Italian Journal of Medicine
Clostridioides difficile infection (CDI) affects the majority of hospital wards. In the context of a Continuing Medical Education Field Training course, a multidisciplinary group of expert healthcare professionals addressed the issue of CDI, producing a
Anna Danise, Federica Furfaro, Gianni Gattuso, Nicola Lucio Liberato, Clara Mandelli, Giuseppe Mazzola, Bianca Osnaghi   +6 more
doaj   +1 more source

In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin

, 2013
Objectives: Current treatments for Clostridium difficile infection include vancomycin, metronidazole, and fidaxomicin. LFF571 is an experimental agent undergoing evaluation in humans for the treatment of moderate C. difficile infection.
Leeds, Jennifer, Sachdeva, Meena, Barnes, Whitney, Ruzin, Alexey, Mullin, Steve   +4 more
core   +1 more source

Fidaxomicin [PDF]

Drugs in R & D, 2010
openaire   +1 more source

Fecal microbiota transplantation versus vancomycin or fidaxomicin in <i>Clostridioides difficile</i> infection first episode and first recurrence: a study protocol for a randomised, controlled, open-label, multicentre phase III clinical trial. [PDF]

BMJ Open
Galpérine T, Erard V, Sommerstein R, Albricht WC, Papadimitriou-Olivgeris M, Gubler M, Brugger SD, Tschudin-Sutter S, Moser M, Cagnon L, Ballif A, Becker D, Moser K, Guery B.   +13 more
europepmc   +1 more source

Fidaxomicin for Clostridiodes difficile infection in inflammatory bowel disease: a multicenter retrospective cohort study

Inflammatory bowel disease (IBD) patients with Clostridiodes difficile Infection (CDI) are at increased risk of disease exacerbations, therapy escalation, colectomy, and mortality. Data on fidaxomicin use in IBD patients with CDI are very limited.
Macaluso, F., Iglesias, R. Ferreiro, Tettoni, E., Zilli, A., Gheorghe, C., Rath, T., Saibeni, S., Dragoni, G., Innocenti, T., Acosta, M. Barreiro-de, Barberio, B., Savarino, E. V., Gisbert, J. P., Bezzio, C., Losco, A., Viganò, C., Cohen, M. Kornowski, Yanai, H., Gabrielli, A. M. Carvalhas, Conforti, F. S., Bossuyt, P., Caprioli, F., Blesl, A., Calderone, S., Chaparro, M., Vieujean, S., Pirola, L., Noviello, D., Atreya, R., Oliveira, R. F. de, Vecchi, M., Molnár, T.   +31 more
core   +1 more source

Fidaxomicin [PDF]

, 2020
openaire   +1 more source

Comparative effectiveness of vancomycin and fidaxomicin in the treatment of Clostridioides difficile-associated diarrhea: A single-center experience in Taiwan. [PDF]

Medicine (Baltimore)
Tseng WC, Chen KC, Chung CS, Tseng PC, Lin CK, Liao CH.   +5 more
europepmc   +1 more source

Effectiveness of fidaxomicin in preventing recurrence after initial community-associated <i>Clostridioides difficile</i> infection. [PDF]

Antimicrob Steward Healthc Epidemiol
Hawco A, Myers C, Dahhan R, Hurley C, van Wijngaarden E, Felsen C, Dumyati G.   +6 more
europepmc   +1 more source

MANAGEMENT OF CLOSTRIDIOIDES DIFFICILE INFECTION IN INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS OF ANTIBIOTIC EFFICACY. [PDF]

Arq Gastroenterol
Pelucio IB, Malaguti C, Oliveira TMD, Chitarra KMSM, Furtado MCV, Chebli JMF.   +5 more
europepmc   +1 more source